Becton, Dickinson and Company (NYSE:BDX) Updates FY 2026 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 12.620-12.720 for the period, compared to the consensus estimate of 12.560. The company issued revenue guidance of -.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Wells Fargo & Company upped their target price on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. UBS Group initiated coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target on the stock. Weiss Ratings downgraded shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Finally, Piper Sandler decreased their target price on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $183.53.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX traded up $6.74 during trading on Thursday, hitting $177.40. 3,285,180 shares of the stock were exchanged, compared to its average volume of 1,774,036. The company has a market cap of $48.88 billion, a PE ratio of 44.91, a P/E/G ratio of 12.16 and a beta of 0.19. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a fifty day moving average price of $153.78 and a two-hundred day moving average price of $162.41. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.Becton, Dickinson and Company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period last year, the business posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, analysts forecast that Becton, Dickinson and Company will post 12.53 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. Becton, Dickinson and Company’s payout ratio is currently 106.33%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $16,122,355.05. This trade represents a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 5,189 shares of company stock worth $765,661. 0.40% of the stock is owned by corporate insiders.

Key Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD reported fiscal Q3 revenue of approximately $5.0 billion, up 5.4% year over year and ahead of the $4.89 billion consensus estimate. Broad growth across its Medical Essentials and Interventional segments helped offset weaker areas. BD Reports Third Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Adjusted diluted EPS was $3.23, beating analysts’ $3.14 estimate by $0.09. The company raised its fiscal 2026 adjusted EPS guidance to $12.62-$12.72, above the roughly $12.56 consensus, and expects revenue growth toward the high end of its previous range. Becton Dickinson Signals Strong Growth Momentum By Raising Profit Outlook
• Positive Sentiment: BD reported solid cash-flow improvement: year-to-date cash from continuing operations rose 33.3% to $2.1 billion, while free cash flow increased 44.6% to $1.7 billion. This supports balance-sheet flexibility and the company’s earnings-quality narrative. BD Reports Third Quarter Fiscal 2026 Financial Results

Institutional Trading of Becton, Dickinson and Company

Hedge funds and other institutional investors have recently bought and sold shares of the company. Brighton Jones LLC grew its stake in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares during the period. Caden Capital Partners LP acquired a new stake in shares of Becton, Dickinson and Company in the fourth quarter worth $101,000. Acumen Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at $120,000. Bank of Jackson Hole Trust lifted its holdings in shares of Becton, Dickinson and Company by 28.8% during the 4th quarter. Bank of Jackson Hole Trust now owns 649 shares of the medical instruments supplier’s stock valued at $126,000 after acquiring an additional 145 shares in the last quarter. Finally, Zions Bancorporation National Association UT lifted its holdings in shares of Becton, Dickinson and Company by 18.3% during the 4th quarter. Zions Bancorporation National Association UT now owns 962 shares of the medical instruments supplier’s stock valued at $187,000 after acquiring an additional 149 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.